Published in J Clin Oncol on February 16, 2010
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol (2015) 5.48
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study. Cancer (2015) 2.13
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer (2015) 1.57
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
Cabazitaxel. Nat Rev Drug Discov (2010) 1.34
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res (2011) 1.32
An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer (2010) 1.32
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer (2011) 1.28
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res (2013) 1.26
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Minireview: Androgen metabolism in castration-resistant prostate cancer. Mol Endocrinol (2013) 1.23
Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res (2012) 1.21
Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther (2013) 1.15
The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am (2011) 1.13
Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian J Androl (2014) 1.12
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2011) 1.11
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem (2011) 1.10
Developing imaging strategies for castration resistant prostate cancer. Acta Oncol (2011) 1.10
AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 1.09
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. J Med Chem (2012) 1.08
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 1.08
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol (2011) 1.06
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist (2014) 1.05
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One (2011) 1.03
Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol (2012) 1.01
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer (2013) 1.01
Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J Med Chem (2013) 1.00
Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol (2010) 0.98
Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol (2012) 0.98
Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem Lett (2011) 0.97
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab (2011) 0.96
20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. Int J Cancer (2012) 0.95
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. Bioorg Med Chem Lett (2012) 0.95
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol (2012) 0.94
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? Front Oncol (2014) 0.93
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol (2012) 0.93
Current treatment strategies for castration-resistant prostate cancer. Korean J Urol (2011) 0.93
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy. Int J Clin Oncol (2012) 0.91
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther (2013) 0.91
MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance. Mol Cancer (2014) 0.90
Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One (2012) 0.90
New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am (2011) 0.90
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol (2012) 0.89
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget (2015) 0.89
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci (2013) 0.88
Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol (2013) 0.87
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl (2011) 0.87
Novel agents in the management of castration resistant prostate cancer. J Carcinog (2014) 0.87
Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis (2014) 0.86
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl (2014) 0.86
Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. Sci Rep (2016) 0.85
Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist (2011) 0.85
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol (2014) 0.85
Novel options for the treatment of castration-resistant prostate cancer. World J Urol (2011) 0.85
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol (2014) 0.84
Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol (2012) 0.84
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids (2015) 0.84
Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res (2014) 0.83
A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer. Hum Gene Ther (2011) 0.83
Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. Br J Cancer (2011) 0.83
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer (2013) 0.82
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas (2010) 0.82
Current management of prostate cancer: dilemmas and trials. Br J Radiol (2012) 0.81
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther (2012) 0.81
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80
Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert. Ther Adv Urol (2012) 0.80
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag (2014) 0.80
Redefining hormone sensitive disease in advanced prostate cancer. Adv Urol (2012) 0.80
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.79
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther (2013) 0.79
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol (2007) 11.04
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol (2008) 3.44
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
Planned versus attained design in phase II clinical trials. Stat Med (1992) 2.90
CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther (2006) 1.71
Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A (2009) 1.52
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer (2006) 1.16
Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res (2005) 1.13
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem (1996) 1.07
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol (2007) 3.51
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol (2005) 3.44
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol (2009) 3.14
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol (2009) 3.11
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00